BENGALURUHYDERABAD, Jan 22 Reuters Indian generic drugmaker Cipla on Monday reported its thirdquarter profit above analysts expectations, boosted by strong performances in North American and domestic markets.

Consolidated net profit rose 32 to 10.56 billion Indian rupees 127.1 million in the quarter ended Dec. 31 from a year earlier, compared with average analysts39; estimate of 10.43 billion rupees, according to LSEG data.

Sales in North America grew 20 during the quarter, partially driven by strong demand for Cipla39;s generic version of Bristol Myers Squibb39;s cancer treatment drug Revlimid. Over the past five quarters, the company has recorded sales growth ranging from 32 to 52 in the region.

Sales in India grew 11.6, helped by robust demand for branded prescription drugs and consumer health products, including popular items such as the rehydration drug ORS and Nicotex, a chewing gum designed to manage the urge to smoke.

The combined revenue from India and the U.S. contribute around 70 to Cipla39;s total revenue.

The overall revenue for the quarter rose by 13.6, surpassing analysts39; expectations of a 12 increase.

Other generic drugmakers such as Dr Reddy39;s and Sun Pharma have also benefitted from sales of their own versions of Bristol Myers Squibb39;s cancer drug.

Meanwhile, Cipla39;s total costs increased about 9, primarily due to inventoryrelated costs and other expenses.

Additionally, there have been reports of the company39;s founding family…